trending Market Intelligence /marketintelligence/en/news-insights/trending/ixRvuAoh4usFwCmEbUt2Yw2 content esgSubNav
In This List

Novartis to fund oral skin cancer drug

Case Study

Identifying PPE Suppliers During the Pandemic


Highlighting the Top Regional Aftermarket Research Brokers by Sector Coverage


COVID-19 Impact & Recovery: Healthcare Outlook for H2 2021


Corporate Credit Risk Trends in Developing Markets: A Loss Given Default (LGD) Perspective

Novartis to fund oral skin cancer drug

Ligand Pharmaceuticals Inc. is partnering with Novartis AG to develop a liquid formulation of Trametinib using its Captisol technology.

Trametinib is used to treat a certain type of skin cancer with Captisol designed to optimize the solubility and stability of drugs.

Novartis will fund the program in exchange for commercialization rights. Ligand will receive an undisclosed license fee as well as royalties on future sales as a result of the agreement.